EFNA4, cell adhesion molecules, and CCR7 expressions of CLL cells in relation to clinical stage and lymphadenopathy
| Case no. . | Stage (Rai)* . | Lymphadenopathy . | EFNA4 . | CD62L . | CD44 . | CD11a (LFA1α) . | CD18 (β2) . | CD49d (VLA-4 α) . | CD29 (β1) . | CCR7 . |
|---|---|---|---|---|---|---|---|---|---|---|
| CLL-1 | Lo | No | 37.23 | 89.44 | 166.23 | 7.64 | 10.63 | 13.91 | 8.26 | 4.07 |
| CLL-2 | Lo | No | 32.58 | 18.96 | 144.93 | 14.98 | 15.46 | 45.06 | 14.01 | 6.73 |
| CLL-3 | Lo | No | 52.36 | 48.81 | 113.39 | 36.41 | 35.25 | 20.62 | 15.81 | 6.35 |
| CLL-4 | Lo | No | 65.56 | 121.52 | 929.44 | 14.62 | 22.73 | 29.89 | 11.60 | 39.23 |
| CLL-5 | Int | Yes | 14.95 | 859.23 | 1376.01 | 24.48 | 79.77 | 133.06 | 15.40 | 24.31 |
| CLL-6 | Int | Yes | 15.23 | 181.91 | 924.52 | 11.40 | 40.72 | 123.45 | 17.84 | 12.56 |
| CLL-7 | Int | Yes | 19.98 | 583.33 | 741.23 | 32.12 | 74.90 | 20.33 | 12.39 | 15.23 |
| CLL-8 | Int | Yes | 23.75 | 706.02 | 939.25 | 13.86 | 16.51 | 29.63 | 18.24 | 14.75 |
| CLL-9 | Hi | Yes | 25.56 | 562.23 | 725.23 | 10.67 | 9.83 | 20.25 | 13.27 | 11.70 |
| CLL-10 | Hi | Yes | 12.65 | 868.62 | 441.25 | 10.87 | 9.08 | 22.52 | 14.01 | 10.76 |
| CLL-11 | Hi | Yes | 35.62 | 444.02 | 333.25 | 13.58 | 10.32 | 12.48 | 18.84 | 8.97 |
| CLL-12 | Hi | No | 36.26 | 649.23 | 689.52 | 19.05 | 11.11 | 7.08 | 25.02 | 10.11 |
| CLL-13 | Hi | No | 25.63 | 1740.21 | 1140.32 | 14.97 | 9.10 | 7.20 | 55.85 | 12.25 |
| Case no. . | Stage (Rai)* . | Lymphadenopathy . | EFNA4 . | CD62L . | CD44 . | CD11a (LFA1α) . | CD18 (β2) . | CD49d (VLA-4 α) . | CD29 (β1) . | CCR7 . |
|---|---|---|---|---|---|---|---|---|---|---|
| CLL-1 | Lo | No | 37.23 | 89.44 | 166.23 | 7.64 | 10.63 | 13.91 | 8.26 | 4.07 |
| CLL-2 | Lo | No | 32.58 | 18.96 | 144.93 | 14.98 | 15.46 | 45.06 | 14.01 | 6.73 |
| CLL-3 | Lo | No | 52.36 | 48.81 | 113.39 | 36.41 | 35.25 | 20.62 | 15.81 | 6.35 |
| CLL-4 | Lo | No | 65.56 | 121.52 | 929.44 | 14.62 | 22.73 | 29.89 | 11.60 | 39.23 |
| CLL-5 | Int | Yes | 14.95 | 859.23 | 1376.01 | 24.48 | 79.77 | 133.06 | 15.40 | 24.31 |
| CLL-6 | Int | Yes | 15.23 | 181.91 | 924.52 | 11.40 | 40.72 | 123.45 | 17.84 | 12.56 |
| CLL-7 | Int | Yes | 19.98 | 583.33 | 741.23 | 32.12 | 74.90 | 20.33 | 12.39 | 15.23 |
| CLL-8 | Int | Yes | 23.75 | 706.02 | 939.25 | 13.86 | 16.51 | 29.63 | 18.24 | 14.75 |
| CLL-9 | Hi | Yes | 25.56 | 562.23 | 725.23 | 10.67 | 9.83 | 20.25 | 13.27 | 11.70 |
| CLL-10 | Hi | Yes | 12.65 | 868.62 | 441.25 | 10.87 | 9.08 | 22.52 | 14.01 | 10.76 |
| CLL-11 | Hi | Yes | 35.62 | 444.02 | 333.25 | 13.58 | 10.32 | 12.48 | 18.84 | 8.97 |
| CLL-12 | Hi | No | 36.26 | 649.23 | 689.52 | 19.05 | 11.11 | 7.08 | 25.02 | 10.11 |
| CLL-13 | Hi | No | 25.63 | 1740.21 | 1140.32 | 14.97 | 9.10 | 7.20 | 55.85 | 12.25 |
Numbers are mean fluorescence intensity (MFI) values as determined by flow cytometry. EFNA4 (MFI) of normal B cells: 8.04 ± 0.23 (mean ± SEM from 3 different samples).
CLL indicates chronic lymphocytic leukemia.
Clinical stage of untreated CLL patients (modified Rai staging) at the moment of blood sampling: low (Lo, Rai 0), intermediate (Int, Rai I-II) and high risk (Hi, Rai III-IV).